Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
Acute kidney injury (AKI)
Cirrhosis
Fractional excretion of sodium (FENa)
Hepatorenal syndrome
Terlipressin
Journal
The Medical clinics of North America
ISSN: 1557-9859
Titre abrégé: Med Clin North Am
Pays: United States
ID NLM: 2985236R
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
medline:
2
6
2023
pubmed:
1
6
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Hepatorenal syndrome (HRS) is a primarily functional form of acute kidney injury (AKI) that develops in patients with decompensated cirrhosis. The pathophysiologic cascade that leads to HRS begins with pooling of blood in the splanchnic system, resulting in a decrease in effective circulating arterial volume. The definitive treatment of HRS is liver transplantation. When this is not possible, HRS is treated with a combination of vasoconstrictor agents and intravenous albumin. Although the combination of midodrine and octreotide is used in the United States, the recently approved terlipressin, an analog of vasopressin, is likely to become the first-line standard of care.
Identifiants
pubmed: 37258014
pii: S0025-7125(23)00042-1
doi: 10.1016/j.mcna.2023.03.009
pii:
doi:
Substances chimiques
Vasoconstrictor Agents
0
Terlipressin
7Z5X49W53P
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-792Informations de copyright
Published by Elsevier Inc.